EUVIMEDEUVIMED entdecken
Multizentrische Studie

Bilateral Anti-VEGF on Same-Day-Investigation on Safety in Retinopathy of Prematurity

Anil Babanrao Gangwe, Anjali Agrawal, Subhadra Jalali, Alay Banker, Tapas Padhi, Parag Shah, Renu P Rajan, Sucheta Kulkarni, Shilpi Shah, Rekha Singhal, Pranab Das, Ajay Kapoor und 12 weitere

Ophthalmology Retina · 2025

DOI: 10.1016/j.oret.2024.11.004 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Ophthalmology Retina, 2025. Verfasst von Anil Babanrao Gangwe und 23 weiteren Autor:innen. Beteiligte Einrichtung: MGM Eye Institute, Raipur, Chhattisgarh, India. Electronic address: anil@mgmeye.org. Hauptthemen laut MEDLINE: Retinopathy of Prematurity, Vascular Endothelial Growth Factor A, Bevacizumab, Ranibizumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To report an incidence of procedure-related complications in preterm infants with retinopathy of prematurity (ROP) treated with intravitreal anti-VEGFs injection in both eyes on the same day. DESIGN: Retrospective, multicenter case series. SUBJECTS: Preterm infants with ROP treated with anti-VEGF bilaterally on the same day. METHODS: All included infants underwent intravitreal anti-VEGF injection in both eyes under aseptic precautions in an ophthalmic operation theater (OT) or neonatal intensive care unit (NICU). A postoperative examination was performed to look for procedure-related complications. MAIN OUTCOME MEASURES: Incidence of procedure-related complication (presumed endophthalmitis, intraocular inflammation, lens injury, vitreous hemorrhage, and retinal tear) in the study cohort. To study the association of indication, type of anti-VEGF, type of needle used, setting of procedure, site of injection (distance from limbus), and experience of the treating ophthalmologist with the complications. RESULTS: Nine thousand nine hundred and eighty-four eyes of 4992 infants were analyzed. The procedure was most commonly performed in ophthalmic OT (8258, 82.7%) using a 29G (4514, 45.2%) needle between 1 and 1.5 mm (9984, 100%) from limbus. Aggressive ROP was the most common indication for anti-VEGF use (4866, 48.7%), whereas Bevacizumab was the most commonly used anti-VEGF agent (8642, 86.6%). Overall, 26 eyes (0.3%) had procedure-related complications. Lens injury (15, 0.15%) and presumed endophthalmitis (7, 0.07%) were the most common complications. One eye had culture-proven endophthalmitis with Pseudomonas aeruginosa. No case of bilateral endophthalmitis was noted. Endophthalmitis was not associated with the setting of a procedure or type of anti-VEGF used, whereas the risk of lens injury was 7 times higher when performed in NICU and 30 times higher when performed by an ophthalmologist with

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinopathy of PrematurityVascular Endothelial Growth Factor ABevacizumabRanibizumabHumansRetrospective StudiesInfant, NewbornAngiogenesis InhibitorsIntravitreal InjectionsMaleFemaleGestational AgeIncidenceFollow-Up StudiesInfant, Premature

Stichwörter der Autor:innen

Anti-VEGFBevacizumabEndophthalmitisRanibizumabRetinopathy of prematurity

Substanzen

Vascular Endothelial Growth Factor AAngiogenesis InhibitorsBevacizumabRanibizumab

Autor:innen und Institutionen

  • MGM Eye Institute, Raipur, Chhattisgarh, India. Electronic address: anil@mgmeye.org.
  • MGM Eye Institute, Raipur, Chhattisgarh, India.
  • LV Prasad Eye Institute, Hyderabad, India.
  • Bankers Retina Clinic and Laser Centre, Ahmedabad, India.
  • LV Prasad Eye Institute, Bhubaneshwar, India.
  • Aravind Eye Hospital, Coimbatore, India.

Zitieren

APA

Gangwe, A. B., Agrawal, A., Jalali, S., Banker, A., Padhi, T., Shah, P., Rajan, R. P., Kulkarni, S., Shah, S., Singhal, R., Das, P., Kapoor, A., Vinekar, A., Bavaskar, S., Vedantham, V., Sanghi, G., Bhattacharya, S., Banker, A., Gaikwad, A., …, & Azad, R. V. (2025). Bilateral Anti-VEGF on Same-Day-Investigation on Safety in Retinopathy of Prematurity. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2024.11.004

Vancouver

Gangwe AB, Agrawal A, Jalali S, Banker A, Padhi T, Shah P, et al. Bilateral Anti-VEGF on Same-Day-Investigation on Safety in Retinopathy of Prematurity. Ophthalmology Retina. 2025. doi:10.1016/j.oret.2024.11.004

BibTeX
@article{Gangwe2025,
  author = {Gangwe, Anil Babanrao and Agrawal, Anjali and Jalali, Subhadra and Banker, Alay and Padhi, Tapas and Shah, Parag and Rajan, Renu P and Kulkarni, Sucheta and Shah, Shilpi and Singhal, Rekha and Das, Pranab and Kapoor, Ajay and Vinekar, Anand and Bavaskar, Snehal and Vedantham, Vasumathy and Sanghi, Gaurav and Bhattacharya, Shashwat and Banker, Ahan and Gaikwad, Anita and Shrivastava, Shivani and Nayak, Sameera and Panchal, Bhavik and Agrawal, Deepshikha and Azad, Raj Vardhan},
  title = {Bilateral Anti-VEGF on Same-Day-Investigation on Safety in Retinopathy of Prematurity},
  journal = {Ophthalmology Retina},
  year = {2025},
  doi = {10.1016/j.oret.2024.11.004}
}
Kostenlos starten →